Bone marrow transplantation (BMT) is the present treatment for hematological malignancies,
Two major drawbacks of allogeneic BMT are graft‐versus‐host disease (GVHD) and …

Examines the association of the therapeutic benefit of allogeneic bone marrow
transplantation with immune-mediated graft-versus-malignancy effect. Information on graft …

Donor lymphocyte infusions can reinduce complete remission in the majority of patients with
chronic myelogenous leukemia (CML) who relapse into chronic phase after allogeneic bone …

To elucidate mechanisms by which T cells eliminate leukemia, we study donor lymphocyte
infusion (DLI), an established immunotherapy for relapsed leukemia. We model T cell …

Introduction: Allogeneic hematopoietic stem cell transplantation (SCT) is the treatment of
choice for many malignant hematological disorders. Following recent improvements in non …

We have recently shown that donor CD4-enriched cells of Th2 cytokine phenotype,
generated by treating mice in vivo with a combination of interleukin-2 (IL-2) and IL-4, prevent …

Increasing evidence across malignancies suggests that infiltrating T cells at the site of
disease are crucial to tumor control. We hypothesized that marrow-infiltrating immune …

Thirty-eight patients with hematological malignancies, received T cell-depleted marrow
transplants (BMT) and cyclosporine to prevent acute graft-versus-host disease (aGVHD) …

" Offers complete coverage and assessment of cell separation technologies for analytical
and preparative isolations of biological cell populations-demonstrating how to select and …

We have recently shown that a short course of high-dose interleukin-2 (IL-2) can markedly
inhibit the graft-versus-host disease (GVHD)-promoting activity of donor CD4+ T cells. The …